In estrogen receptor–positive breast cancer, ZIF-8 nanoparticles were employed to co-deliver antisense oligonucleotides (ASOs) targeting circTNK2 and plasmids encoding CXCL10 (101, 157). The gene discussed is ESR1; the disease is breast carcinoma.